Gamida Cell Shares Up 34% on FDA Approval of Omisirge Cell Therapy for Blood Cancer

By Josh Beckerman


Gamida Cell Ltd. shares rose 34% to $1.08 Monday after the U.S. Food and Drug Administration approved the Boston-based biotechnology company's Omisirge cell therapy for... | April 17, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Josh Beckerman ,Gamida Cell Ltd ,Drug Administration ,Dow Jones ,Gamida Cell Ltd Stock Exchange ,News ,Information ,Press Release ,Y ,Josh ,Beckerman ,Shamida ,Fell ,Hares ,Nose ,O ,Monday ,After ,The ,Wood ,End ,Drug ,Administration ,Approved ,Biotechnology ,Misirge ,Herapy Gmda Il0011552663 ,